Shri. D. D. Vispute College of Pharmacy and research Centre Panvel Navi Mumbai.
Hairy cell?leukemia (HCL) is an uncommon chronic lymphoid neoplasm characterized by unique clinical and laboratory findings. Historically, it has responded to?multiple treatment modalities, though none are curative. Newer treatment options for relapsed or refractory HCL remain limited, especially?in patients with novel purine analog refractory disease or those with high-risk molecular mutations including BRAFV600E. This will have implications for resistance mechanisms, functional scoring systems, and the timing of new?targeted therapies in the treatment trajectory to improve patient outcomes. This study seeks to improve the?understanding of HCL by overcoming the limitations associated with currently available treatment strategies, especially in relapsed or refractory cases. Findings show?that the addition of purine analogs to agents such as rituximab increases response rates. Overcoming resistance There is evidence to?suggest that novel targeted strategies, including the use of BRAF and MEK inhibitors, do effectively overcome this resistance. Immunotoxins?and newer monoclonal antibodies are on the horizon. In the research findings of HCL interpretation should rotation study how observed data provide insight into the underlying pathophysiology; it enhances diagnostic accuracy; or it has impact on?treatment strategies. The discovery of the?BRAFV600E mutation in the majority of HCL cases has important implications for elucidating the pathogenesis of the disease, revealing insights into oncogenic signaling pathways.[1][2].
Hairy cell leukemia (HCL), a rare and indolent B-cell chronic lymphoproliferative disorder initially reported by Bouroncle and colleagues in 1958. This distinctive malignancy associated with the pancytopenia and splenomegaly that accounted for 2% of all leukemias. HCL is four to five times more frequent in men than women. HCL cells characterized by a spongy appearance of the nucleus and a blue cytoplasm with an irregular, serrated border. While the cell of origin of this leukemia has been ascribed to a mature monoclonal B cell based upon the expression of CD19, surface immunoglobulin, and clonal rearrangements of immunoglobulin genes, recent studies suggest that the pathogenesis of this disorder involves mutations in the hematopoietic stem cells. [3]The epidemiology remains only partially elucidated, with occupations involving exposure to diesel fuel, organic solvents, large animal farming, and pesticide and herbicide exposure being implicated in the development of the disease.[4] While patients may present at any. Age throughout adult life, the median age at diagnosis is approximately 55 years old. In the 1980s, splenectomy was the standard treatment. Interferon alpha (IFN-α) was subsequently introduced and used until the early 2000s . Then the purine nucleoside analogues (PNAs) pentostatin (2’-deoxycoformycin) and cladribine (2-chlorodeoxyadenosine) were introduced; these drugs are currently the first-line therapeutic option for symptomatic HCL patients. New drugs have recently emerged, especially BRAF inhibitors (BRAFi) (vemurafenib, dabrafenib), BRAFi associated with MEK inhibitors (trametinib, cobimetinib), CD22-targeted therapy and BCR inhibitors (BCRi) (ibrutinib). In all HCL cases, long-term follow-up is mandatory because of the risk of relapses and secondary malignancies. A recent study including 357 patients (265 men, 92 women) showed a better prognosis in women, with a time to next treatment (TTNT) of 17.6 years in women as compared to only 8 years in men.[5] Relapsed or refractory disease remained a treatment challenge until the identification of BRAFV600E mutations as the causal genetic abnormality, offering a targeted therapy for this pretreated population . Classic HCL (HCLc) and HCL variant (HCLv) have unique immunophenotypic and molecular differences with an overwhelming majority of HCLc harboring a BRAF V600E mutation and following an indolent course. BRAF V600E mutation is absent in HCLv, has an aggressive clinical course, and is less responsive to standard therapies. We describe a case of relapsed BRAF-mutated HCLc presenting with hyperlymphocytosis and intracranial involvement that was successfully treated with the oral BRAF inhibitor, rituximab. [6] BRAFV600E mutation is an early and central genetic driver in HCL. Using whole-exome sequencing (WES) in 2011, BRAFV600E somatic mutation was found in a patient with HCL40 BRAF proto-oncogene (BRAF gene) (7q34) is composed of 18 exons: the mutation occurs in exon 15 at position 1799, in which thymine and adenine are exchanged, leading to valine (V) being substituted by glutamic acid (E) at codon 600 (V600E) of the BRAF protein.[7] The mutation was subsequently identified in up to 90%-100% of HCL cases. The BRAFV600E mutation constitutively activates BRAF by autophosphorylation of the protein and downstream mitogen-activated protein kinase- extracellular-signal-regulated kinase (MEK-ERK) signaling pathway, leading to increased expression of genes involved in survival and proliferation such as members of the ETS family, FOS, MYC as well as of genes involved in MEK/ERK inhibition such as dual-specificity phosphatases (DUSPs).[8]
Diagnostic Criteria for Hairy Cell Leukemia (HCL) :
Diagnosis is based on a combination of clinical, morphological, immunophenotypic, and genetic criteria. Here are the key diagnostic criteria:
Hairy Cells Express:
The presence of hairy cells in blood/bone marrow, along with the characteristic immunophenotype and BRAF V600E mutation, confirms HCL.[11]
Review of Current HCLF Guidelines
The Hairy Cell Leukemia Foundation (HCLF) has played a pivotal role in establishing consensus guidelines for the diagnosis and management of classic hairy cell leukemia (HCL). In an international conference, the HCLF convened experts to develop standardized definitions and treatment protocols to guide clinicians worldwide. These guidelines emphasize the importance of accurate diagnosis, appropriate initiation of therapy, and considerations for relapse management. They also highlight the need for ongoing research, particularly in understanding minimal residual disease and improving infection prevention strategies. For patients and families, the HCLF offers a wealth of educational resources, including webinars and forums that provide insights into the latest treatment options and research developments.[12] They also maintain a comprehensive patient data registry to facilitate research and improve patient outcomes. As of February 2025, the Hairy Cell Leukemia Foundation (HCLF) continues to provide comprehensive guidelines for the diagnosis and management of classic hairy cell leukemia (HCL). In response to the COVID-19 pandemic, the HCLF convened experts to adapt existing guidelines, considering the increased infection risks for HCL patients. These adaptations recommend active surveillance for patients with stable blood counts, the use of targeted, non-immunosuppressive agents as first-line treatments, and preventive measures against COVID-19.[37] They also maintain a comprehensive patient data registry to facilitate research and improve patient outcomes. In summary, the HCLF’s guidelines serve as a foundational framework for the effective diagnosis and management of hairy cell leukemia, aiming to standardize care and improve patient outcomes globally.[13]
Indications for Treatment-
Hairy cell leukemia is a rare, slow-growing B-cell malignancy. It typically presents with the following clinical and laboratory features such as clinical features, laboratory findings. Hairy cell leukemia is highly responsive to therapy. The treatment approach depends on the patient’s disease burden, symptoms, and response to prior therapy.[14]
Summary of First-Line Therapy
|
Treatment |
Route & Duration |
Complete Remission Rate |
Key Considerations |
|
Cladribine (2-CdA) |
IV for 5–7 days or SC over 5–7 days |
~85–90% |
Preferred first-line; risk of infections |
|
Pentostatin |
IV every 2 weeks |
~80% |
Used if Cladribine is not an option |
|
Rituximab |
IV weekly for 4–8 weeks |
Varies |
Used in relapsed/refractory cases |
|
Vemurafenib (BRAF inhibitor) |
Oral |
~90% (for BRAF V600E mutation) |
Minimal immunosuppression |
|
Moxetumomab Pasudotox |
IV infusion (3 cycles) |
~75% |
Used for relapsed cases; renal toxicity risk |
Response Assessment
Response to rituximab therapy was assessed during the first 6 months following the end of treatment, depending on available data. Complete hematologic response (CHR) was defined As (i) the recovery of normal blood counts (absolute neutrophil Count (ANC) ≥1.5×109/L, hemoglobin level ≥120 g/L for Men and ≥110 g/L for women, and platelet count ≥100×109/L) and (ii) the absence of circulating HCL cells and clinical.[15] Signs (mainly splenomegaly and hepatomegaly) of HCL; depending on the availability of a BM assessment after rituximab therapy, CHR was further divided into three subgroups: Stringent complete response (sCR) if BM evaluation showed. No persistent leukemic cells, unconfirmed complete response(uCR) if no BM trephine biopsy or aspirate was performed. after treatment, and CHR with persistent medullar infiltration By leukemic cells (iCHR). Partial response (PR) was defined As a ≥50 % improvement for every CHR-defining criterion or Normalization of at least one blood count (ANC, hemoglobin Level, or platelet count), without circulating HCL cells. Patients not meeting criteria for at least PR were classified asNon-responders (NR).[16]
Contraindications to Treatment
Patients with active infections, significant renal dysfunction, pregnancy, or underlying neurological abnormalities may not be eligible initially to receive a PA. Traditionally, for this group of patients, interferon alpha has been successfully utilized to improve peripheral blood counts and can serve as a bridge to more definitive therapy once the contraindication has resolved. In a case series that included 3 treatment-naïve HCL patients with contraindications to PA, the combination of rituximab with a short duration of vemurafenib was well tolerated and achieved durable remissions.[17] Splenectomy also remains an option, although it should be used as a bridging therapy until a post-partum PA can be used as it only improves blood counts but has no pathological remissions; splenectomy could also carry an increased risk of bleeding and surgical complications in late pregnancy. Data on rituximab during pregnancy remains inconclusive, with studies showing no clear pattern of anomalies related to its use.[18]
Rituximab is a monoclonal antibody therapy that's used to treat various cancers and immune disorders.
Yes, Rituximab (Rituxan) is a monoclonal antibody that treats various cancers and immune disorders. It’s given as an intravenous injection. Rituximab attaches to the CD20 protein on B cells. The immune system then identifies and destroys the marked cells. Rituximab is a monoclonal antibody that specifically targets the CD20 protein found on the surface of B-cells. It’s commonly used to treat a variety of conditions, including cancers such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as autoimmune disorders like rheumatoid arthritis and vasculitis. By binding to the CD20 protein, Rituximab helps destroy B-cells, which may be abnormal or overactive in these diseases. This mechanism aids in regulating the immune system and controlling disease progression.[12][19]
Case Study
Hairy cell leukemia is a rare, indolent, chronic B-cell malignancy characterized by pancytopenia, splenomegaly, and infiltration of bone marrow by abnormal lymphocytes with cytoplasmic projections. While purine analogs such as cladribine and pentostatin are first-line therapies, some patients experience relapse or resistance. Rituximab, a monoclonal antibody targeting CD20, has emerged as a potential treatment for relapsed or refractory HCL.[20]
Case Study 1:
A 52-year-old male was suffering from fatigue, recurrent infections, pancytopenia. The bone marrow biopsy was confirmed classic HCL with CD20.The treatment history that he has done was first line therapy cladribine 5 days IV course. It get relapse, after 3 yrs later with worsening cytopenia So, after this second line therapy was done in that Pentostatin was given but not get sustained response. After that the Rituximab (375 mg/m²) weekly for 4 weeks. After giving Rituximab the outcomes was seen that in short term response the peripheral blood counts gets improved after 2 cycles. The bone marrow biopsy after 3 months post treatment shows no evidence of hairy cells. The Minimal Residue disease (MRD) shows negative for CD20+ cells.[21][22]
DISCUSSION
The mechanism of action of Rituximab targets CD20, leading to B-cell depletion via complement-dependent cytotoxicity and apoptosis. The Clinical trials show rituximab is effective in relapsed/refractory HCL, with response rates of 70-80% in some studies. Tolerability of Rituximab in this case is Well-tolerated, with only mild infusion reactions.[23]
CONCLUSION
This case highlights rituximab as an effective option for relapsed HCL, especially in patients resistant to purine analogs. Further studies may refine dosing strategies and explore combination therapies with BRAF or BTK inhibitors.[24]
Case Study 2:
The 56-year-old male was there. Hus medical history was he was not having prior medical conditions other than mild hypertension. Recently diagnosed with Hairy Cell Leukemia (HCL) following a routine blood test revealing pancytopenia (low levels of red blood cells, white blood cells, and platelets). Bone marrow biopsy confirmed the diagnosis of HCL.[25]
Diagnosis:
HCL is a rare type of leukemia characterized by the proliferation of atypical B lymphocytes that have "hairy" projections when viewed under a microscope. These cells infiltrate the bone marrow, spleen, and liver, causing symptoms such as fatigue, splenomegaly (enlarged spleen), hepatomegaly (enlarged liver), and pancytopenia. Diagnostic tests was done like peripheral blood smear in that hairy cells with characteristics projections has shown, Bone marrow Biopsy in this it confirmed the presence of hairy cells, Flow cytometry it has shown the presence of CD20, CD22, and CD11c markers.[26][27]
Treatment Plan:
The initial treatment approach was to use Rituximab, a monoclonal antibody targeting CD20, which is highly expressed on the surface of hairy cells. Rituximab works by binding to CD20 and inducing apoptosis in these malignant cells. It also facilitates immune-mediated destruction of the leukemic cells. Rituximab was administered intravenously in a standard regimen of 375 mg/m² once weekly for four weeks.[28]
Week 1: 375 mg/m² Rituximab IV, Week 2: 375 mg/m² Rituximab IV, Week 3: 375 mg/m² Rituximab IV, Week 4: 375 mg/m² Rituximab IV. The treatment was well tolerated with no major adverse reactions during the infusion. Common side effects, such as fever and chills, were noted after the first dose but resolved with supportive care (e.g., acetaminophen and diphenhydramine). Then after follow up and monitoring the baseline lab values such as White blood cell count (WBC): 1,200/µL, Hemoglobin: 9.5 g/dL, Platelet count: 50,000/µL, Peripheral blood smear showed the characteristic "hairy cells." Then after 3 months again follow up was done it has shown that patient's spleen size reduced significantly. The Peripheral blood counts improved. White blood counts: 4,500/µL, Hemoglobin: 12.5 g/dL, Platelet count: 150,000/µL, Bone marrow biopsy after three months showed a reduction in hairy cell infiltration, confirming a partial remission.[29][30][38]
Outcome:
The patient showed significant improvement in symptoms and lab values, with the resolution of splenomegaly and normalization of blood counts. Rituximab therapy was deemed highly effective in this patient with HCL. After the initial 4-week treatment, the patient was monitored for any relapse, with regular follow-up appointments scheduled every three months for the first year. [31[32]
DISCUSSION:
Hairy Cell Leukemia is a rare malignancy of B lymphocytes, and treatment options have evolved over the years. Traditionally, purine nucleoside analogs (PNA) like cladribine and pentostatin were the primary treatment.[33] However, Rituximab has emerged as an effective therapeutic option, especially for patients who may not tolerate or respond to traditional treatments. Rituximab targets CD20 on malignant B cells, leading to their destruction via antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and direct apoptosis.[34] The combination of Rituximab with other agents, such as cladribine, has also shown promising results in some cases, though Rituximab as monotherapy can be highly effective for patients with indolent forms of HCL. Long-term remission is achievable, and Rituximab’s safety profile in HCL is generally favorable.[35][36]
CONCLUSION:
In this case, Rituximab therapy was successful in achieving remission for the patient with Hairy Cell Leukemia, demonstrating its role as an effective treatment option for this rare cancer. Further monitoring is required to assess for any signs of relapse, and ongoing research into combination therapies may offer even more robust options in the future.[39][40]
REFERENCES
Pranay Uplenchwar*, Vaidehi Gandhi, Vaishnavi Tambe, Dr. Ashish Jain, A Systematic Review of a Documented Case Study That Examined Advanced Approaches to Therapy for Hairy Cell Leukemia, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 3, 2819-2828 https://doi.org/10.5281/zenodo.15100664
10.5281/zenodo.15100664
